Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HANNA D ZEMBRZUSKA

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1336346352
CMS profile
657576
Location
IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$272.15

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $252.90 2
Education $19.25 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $130.13 1
Boehringer Ingelheim Pharmaceuticals, Inc. $122.77 1
SOBI, INC $19.25 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HANNA D ZEMBRZUSKA

NPI 1336346352 · CMS profile ID 657576

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336346352?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HANNA D ZEMBRZUSKA, NPI 1336346352, CMS profile ID 657576. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336346352?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HANNA D ZEMBRZUSKA, NPI 1336346352, CMS profile ID 657576. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336346352?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HANNA D ZEMBRZUSKA, NPI 1336346352, CMS profile ID 657576, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1336346352?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $272.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $122.7711/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117969190 CMS
Novartis Pharmaceuticals Corporation $130.1311/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087438386 CMS
SOBI, INC $19.2509/18/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141433915 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $1,925.92 9
PY2024 $272.15 3
PY2025 $27,361.02 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $611,511.60 15
PY2024 Principal investigator $742,907.77 24
PY2023 Principal investigator $152,746.77 10
PY2022 Principal investigator $120,816.03 2
PY2021 Principal investigator $178.00 1
PY2019 Recipient $1,360.48 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,126.00 12/17/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory Myopathies (IIM) No dispute reported 06/30/2026 1089695347
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,714.08 11/08/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1089685013
Principal investigator 1 Novartis Pharmaceuticals Corporation $40,935.00 10/17/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1089694749
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $33,670.00 10/14/2024 Non-covered Recipient Entity
State University Of Iowa Ste 168c
sGC activator in SSc patients No dispute reported 06/30/2026 1101070303
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,267.51 10/01/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory Myopathies (IIM) No dispute reported 06/30/2026 1089684881
Principal investigator 1 Novartis Pharmaceuticals Corporation $44,791.00 09/26/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN) No dispute reported 06/30/2026 1089694261
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,126.00 09/26/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis. No dispute reported 06/30/2026 1089695319
Principal investigator 1 Novartis Pharmaceuticals Corporation $34.24 09/15/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1089685019
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,264.89 09/01/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis. No dispute reported 06/30/2026 1089685743
Principal investigator 1 Novartis Pharmaceuticals Corporation $76,248.28 09/01/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) No dispute reported 06/30/2026 1089685755
Principal investigator 1 Novartis Pharmaceuticals Corporation $37,987.00 08/27/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1089694933
Principal investigator 1 Novartis Pharmaceuticals Corporation $525.05 08/01/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis. No dispute reported 06/30/2026 1089684961
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,889.01 07/25/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN) No dispute reported 06/30/2026 1089685121
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,441.20 07/23/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1089695197
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,150.00 07/15/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1089685079
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11.03 07/12/2024 Non-covered Recipient Entity
University Of Iowa Healthcare
sGC activator in SSc patients No dispute reported 06/30/2026 1101070305
Principal investigator 1 Boehringer Ingelheim International GmbH $1,482.95 07/01/2024 Non-covered Recipient Entity
University Of Iowa Healthcare
sGC activator in SSc patients No dispute reported 06/30/2026 1101074909
Principal investigator 1 Janssen Research & Development, LLC $4,705.00 06/07/2024 Non-covered Recipient Entity
Univ Of Ia
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome pSS No dispute reported 06/30/2026 1078961557
Principal investigator 1 Janssen Research & Development, LLC $990.00 06/07/2024 Non-covered Recipient Entity
Univ Of Ia
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome pSS No dispute reported 06/30/2026 1078961561
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,869.84 06/01/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN) No dispute reported 06/30/2026 1089685151
Principal investigator 1 Novartis Pharmaceuticals Corporation $74,788.20 03/12/2024 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) No dispute reported 06/30/2026 1089694987
Principal investigator 1 Janssen Research & Development, LLC $4,409.00 02/07/2024 Non-covered Recipient Entity
Univ Of Ia
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome pSS No dispute reported 06/30/2026 1078961559
Principal investigator 1 Novartis Pharmaceuticals Corporation $83,294.17 01/08/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1089684847
Principal investigator 1 Novartis Pharmaceuticals Corporation $243,188.32 01/01/2024 Non-covered Recipient Entity
UNIVERSITY OF IOWA
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) No dispute reported 06/30/2026 1089684839